Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001205870 | SCV001377150 | uncertain significance | Granulomatous disease, chronic, autosomal recessive, cytochrome b-negative | 2021-08-28 | criteria provided, single submitter | clinical testing | This sequence change replaces proline with leucine at codon 180 of the CYBA protein (p.Pro180Leu). The proline residue is weakly conserved and there is a moderate physicochemical difference between proline and leucine. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate insufficient coverage at this position in the ExAC database. This variant has not been reported in the literature in individuals affected with CYBA-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001828650 | SCV002089421 | uncertain significance | Chronic granulomatous disease | 2021-04-05 | no assertion criteria provided | clinical testing |